Avacta AVA6000 (Faridoxorubicin) ASCO 2026 Update: FAP-Activated Doxorubicin Conjugate Holds Salivary-Gland Responses at a Dose Three Times Conventional Doxorubicin's Ceiling
On June 1 Avacta reported updated Phase 1a/1b data for faridoxorubicin (AVA6000), a pre|CISION-enabled, FAP-activated doxorubicin peptide-drug conjugate that releases its payload inside the tumor microenvironment. At the recommended expansion dose of 310 mg/m², nearly three times conventional doxorubicin's 75 mg/m² maximum tolerated dose, toxicity stayed below historical doxorubicin rates, and the salivary gland cancer cohort held multiple confirmed responses: four partial and nine minor responses among 38 evaluable patients.